CaAKG

Tmrw Clinical Studies — CaAKG

▣ 2026

♟ 3

⚗ Tmrw's current Clinical Studies dashboard lists a CaAKG entry described as a multi-center, randomized, double-blind study on healthy-aging endpoints, with methylation and clinical outcomes. The crawled page does not expose the underlying paper URL, so this links to the Tmrw research library itself.

Read More →

Taurine

Tmrw Clinical Studies — Taurine

▣ 2025

♟ 10

⚗ Tmrw's clinical-studies dashboard currently lists taurine under cardiometabolic helpers and displays two taurine study cards: one on ventilator-associated pneumonia in critically ill pediatric patients and another examining long-term taurine supplementation, brain mitochondrial function and neurological outcomes.

CaAKG

Tmrw CaAKG ingredient page

▣ 2026

♟ 3

⚗ Tmrw currently lists CaAKG at about 950–1000 mg and describes metabolism/cellular longevity or mitochondrial-energy/healthy-inflammation support. This is a manufacturer claim, not independent evidence.

Read More →

CAAKG

ABLE — 2025 recruitment evaluation

▣ 2026

♟ 5

⚗ 120 healthy adults aged 40–60; randomized, double-blind, placebo-controlled; 1 g/day sustained-release Ca-AKG vs placebo; 6 months plus 3-month follow-up. Primary endpoint: DNA-methylation age. The 2025 paper evaluates recruitment feasibility, not efficacy results.

Read More →

Taurine

Taurine and blood pressure in prehypertension

▣ 2025

♟ 10

⚗ 120 prehypertensive adults; 1.6 g/day; 12 weeks; randomized, double-blind, placebo-controlled. Reported reductions in blood pressure and improved vascular function.

Read More →

CAAKG

ABLE — full protocol

▣ 2026

♟ 5

⚗ Randomized, double-blind, placebo-controlled trial of 1 g/day sustained-release Ca-AKG vs placebo for 6 months in 120 middle-aged adults with higher DNA-methylation age.

Read More →

CAAKG

ABLE — PMC full text

▣ 2025

♟ 10

⚗ Open-access version of the ABLE protocol; registered as NCT05706389

Read More →

Taurine

Taurine and blood pressure/vascular function in T2D — 2025

▣ 2025

♟ 10

⚗ Placebo controlled

◉ Peer reviewed

Read More →

Taurine

Tmrw Taurine article

▣ 2025

♟ 10

⚗ Tmrw's May 2026 taurine article states that its product contains 1,200 mg taurine per scoop and discusses human evidence, including a 2024 meta-analysis of 25 human trials. This is Tmrw's interpretation, not independent evidence.

Read More →

CAAKG

NCT07114536 — CaAKG and biological aging

▣ 2025

♟ 10

⚗ Randomized, double-blind, placebo-controlled; estimated 30 adults aged 45–75; 2 g/day CaAKG for 12 weeks. Primary endpoint: PhenoAge. Current registry status: active, not recruiting; no results posted.

Read More →

CAAKG

NCT07269704 — age-related ocular disease

▣ 2025

♟ 10

⚗ Stanford open-label, single-arm early-phase study; 17 participants. CaAKG 2 g/day around cataract surgery; examined aqueous-humor aKG and metabolic/retinal pathways

Read More →

CAAKG

Healthy subjects — 1990

▣ 2025

♟ 10

⚗ Six healthy men; 3.6 g alpha-ketoglutarate as calcium alpha-ketoglutarate; five-hour blood sampling for amino acids, alpha-KG, insulin and glucagon. Human pharmacology/metabolism study.

Read More →

CAAKG

Hemodialysis — 1996

▣ 2025

♟ 10

⚗ 24 malnourished hemodialysis patients received CaAKG for one year. Plasma arginine increased; phosphate and urea decreased. PubMed classifies it as a clinical trial/comparative study.

Read More →

Taurine

T2D — glycemic control and lipids

▣ 2025

♟ 10

⚗ 45 patients; 3 g/day; 8 weeks; randomized, double-blind, placebo-controlled. FBS, insulin, HOMA-IR, total cholesterol and LDL-C decreased; HbA1c, triglycerides and HDL-C did not significantly change.

◉ Peer reviewed

Read More →

CAAKG

Hemodialysis / hyperparathyroidism — 1996

▣ 2025

♟ 10

⚗ 14 hemodialysis patients received mean 4.5 g/day Ca-alpha-ketoglutarate for 36 months. Serum phosphate decreased and intact PTH normalized.

◉ Peer reviewed

Read More →

CAAKG

Biological-age cohort — 2026

▣ 2025

♟ 10

⚗ Cross-sectional cohort of 4,260 health enthusiasts. A delayed-release Ca-AKG + vitamin product was associated with an average 1.8-year lower biological-age residual. Observational; cannot establish causation.

Read More →

CAAKG

Hemodialysis / hyperparathyroidism — 1996

▣ 2025

♟ 10

⚗ 14 hemodialysis patients received mean 4.5 g/day Ca-alpha-ketoglutarate for 36 months. Serum phosphate decreased and intact PTH normalized.

Read More →

CAAKG

Biological-age cohort — 2026

▣ 2025

♟ 10

⚗ Cross-sectional cohort of 4,260 health enthusiasts. A delayed-release Ca-AKG + vitamin product was associated with an average 1.8-year lower biological-age residual. Observational; cannot establish causation.

Read More →

CAAKG

Biological-age cohort — 2026

▣ 2025

♟ 10

⚗ Cross-sectional cohort of 4,260 health enthusiasts. A delayed-release Ca-AKG + vitamin product was associated with an average 1.8-year lower biological-age residual. Observational; cannot establish causation.

Read More →

Vitamin C

Biological-age cohort — 2026

▣ 2025

♟ 10

⚗ Cross-sectional cohort of 4,260 health enthusiasts. A delayed-release Ca-AKG + vitamin product was associated with an average 1.8-year lower biological-age residual. Observational; cannot establish causation.

Read More →

Trans-Resveratrol

Trans-resveratrol and visible skin ageing

▣ 2025

♟ 10

Read More →

Trans-Resveratrol

Resveratrol in older overweight adults

▣ 2025

♟ 10

⚗ Study design / population: 32 older overweight adults; 300 or 1,000 mg/day; 12 weeks; randomized placebo-controlled.

Read More →

Trans-Resveratrol

Resveratrol, memory and hippocampal function

▣ 2025

♟ 10

⚗ Study design / population: 46 healthy overweight older adults; 200 mg/day; 26 weeks; randomized controlled trial.

Read More →

Trans-Resveratrol

Resveratrol and memory in elderly adults

▣ 2025

♟ 10

⚗ Reported findings: No significant improvement in the primary verbal-memory outcome was reported.

Read More →

Trans-Resveratrol

Resveratrol, cerebral blood flow and cognition

▣ 2025

♟ 10

⚗ Placebo controllStudy design / population: 22 healthy adults; 250 and 500 mg; randomized, double-blind, placebo-controlled crossovered

◉ Peer reviewed

Read More →

Trans-Resveratrol

Resveratrol, cerebral blood flow and cognition

▣ 2025

♟ 10

⚗ Study design / population: 23 adults; 250 mg trans-resveratrol ± piperine; randomzed, double-blind, placebo-controlled crossover.

◉ Peer reviewed

Read More →

Trans-Resveratrol

Chronic trans-resveratrol in young adults

▣ 2025

♟ 10

⚗ Study design / population: 60 young adults; 28 days; randomized, double-blind, placebo-controlled.

◉ Peer reviewed

Read More →

SKIN CARE

Postmenopausal women: cognition and cerebrovascular function

▣ 2025

♟ 10

⚗ Study design / population: 80 women aged 45–85; 14 weeks; randomized placebo-controlled.

◉ Peer reviewed

Read More →

SKIN CARE

Skin deterioration

▣ 2025

♟ 10

⚗ Design / population: 65 healthy women; 6 or 12 mg/day; 16 weeks; randomized clinical study

◉ Peer reviewed

Read More →

SKIN CARE

Visual function

▣ 2025

♟ 10

⚗ Design / population: 60 healthy adults; 9 mg/day; 6 weeks; randomized, double-blind, placebo-controlled

◉ Peer reviewed

Read More →